Asset Details
Do you wish to reserve the book?
BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma
Do you wish to request the book?
BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma
2020
Overview
Synovial sarcoma (SS) is an aggressive tumor that most often affects the deep soft tissues in young adults. Intrathoracic SS is rare and is associated with poor outcome, highlighting the urgent need for a novel therapeutic strategy. In the process of clinical sequencing, we identified two patients with intrathoracic SS harboring the BRAF V600E mutation. The patients were women aged 32 and 23 years, and both presented with SS18–SSX2-positive monophasic SS in the thoracic cavity. BRAF V600E mutations were detected by next generation sequencing, and validated immunohistochemically by diffuse intense positivity to BRAF V600E mutation-specific antibodies. The phosphorylated ERK (pERK) immunohistochemistry result was also positive. One patient received a combination therapy of dabrafenib and trametinib, which led to tumor shrinkage. However, the tumor growth progressed 7.5 months later with an additional NRAS Q61K mutation. Immunohistochemical screening of 67 archival SS tumor samples failed to identify additional samples with BRAF V600E mutation. However, 32% of BRAF V600E-negative cases was positive for pERK, and one of the six tumors showing the highest pERK expression harbored an FGFR2-activating mutation. This is the first report of targetable BRAF mutation in a small subset of SS. Our study suggests involvement of the mitogen-activated protein kinase pathway and the potential clinical implication of BRAF mutation screening in SS.
Publisher
Elsevier Inc,Nature Publishing Group US,Elsevier Limited
Subject
/ Adult
/ Atrophy
/ Biomarkers, Tumor - genetics
/ Extracellular signal-regulated kinase
/ Female
/ Fibroblast growth factor receptor 2
/ Humans
/ Kinases
/ MAP Kinase Signaling System - drug effects
/ MAP Kinase Signaling System - genetics
/ Mediastinal Neoplasms - drug therapy
/ Mediastinal Neoplasms - genetics
/ Mediastinal Neoplasms - metabolism
/ Mediastinal Neoplasms - pathology
/ Medicine
/ Mutation
/ Protein Kinase Inhibitors - pharmacology
/ Protein Kinase Inhibitors - therapeutic use
/ Proto-Oncogene Proteins B-raf - genetics
/ Sarcoma
/ Sarcoma, Synovial - drug therapy
/ Sarcoma, Synovial - genetics
/ Sarcoma, Synovial - metabolism
/ Sarcoma, Synovial - pathology
/ Thorax
/ Tumors
